Risk prediction for dermatomyositis-associated hepatocellular carcinoma.
Dermatomyositis
Hepatocellular carcinoma
PI3K/ART signaling pathway
SPP1
Support vector machine
Journal
BMC bioinformatics
ISSN: 1471-2105
Titre abrégé: BMC Bioinformatics
Pays: England
ID NLM: 100965194
Informations de publication
Date de publication:
31 May 2023
31 May 2023
Historique:
received:
02
02
2023
accepted:
25
05
2023
medline:
2
6
2023
pubmed:
1
6
2023
entrez:
31
5
2023
Statut:
epublish
Résumé
To explore dermatomyositis signature genes as potential biomarkers of hepatocellular carcinoma and their associated molecular regulatory mechanisms. Based on the mRNA-Seq data of dermatomyositis and hepatocellular carcinoma in public databases, five dermatomyositis signature genes were screened by LASSO regression analysis and support vector machine (SVM) algorithm, and their biological functions in dermatomyositis with hepatocellular carcinoma were investigated, and a nomogram risk prediction model for hepatocellular carcinoma was constructed and its predictive efficiency was initially evaluated. The immune profile in hepatocellular carcinoma was examined based on the CIBERSORT and ssGSEA algorithms, and the correlation between five dermatomyositis signature genes and tumor immune cell infiltration and immune checkpoints in hepatocellular carcinoma was investigated. The expression levels of five dermatomyositis signature genes were significantly altered in hepatocellular carcinoma and showed good diagnostic efficacy for hepatocellular carcinoma, suggesting that they may be potential predictive targets for hepatocellular carcinoma, and the risk prediction model based on five dermatomyositis signature genes showed good risk prediction efficacy for hepatocellular carcinoma and has good potential for clinical application. In addition, we also found that the upregulation of SPP1 expression may activate the PI3K/ART signaling pathway through integrin-mediated activation, which in turn regulates the development and progression of hepatocellular carcinoma. LY6E, IFITM1, GADD45A, MT1M, and SPP1 are potential predictive targets for new-onset hepatocellular carcinoma in patients with dermatomyositis, and the upregulation of SPP1 expression may activate the PI3K/ART signaling pathway through the mediation of integrins to promote the development and progression of hepatocellular carcinoma.
Identifiants
pubmed: 37259059
doi: 10.1186/s12859-023-05353-6
pii: 10.1186/s12859-023-05353-6
pmc: PMC10233868
doi:
Substances chimiques
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
222Informations de copyright
© 2023. The Author(s).
Références
Medicine (Baltimore). 2018 Aug;97(33):e11586
pubmed: 30113453
Am J Transl Res. 2019 Mar 15;11(3):1760-1770
pubmed: 30972199
Biomed Pharmacother. 2018 Dec;108:347-354
pubmed: 30227328
Clin Cancer Res. 2015 Jul 15;21(14):3252-62
pubmed: 25862760
Korean J Intern Med. 2014 Mar;29(2):231-5
pubmed: 24648807
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Oral Pathol Med. 2022 Aug;51(7):620-629
pubmed: 35822409
Zhonghua Gan Zang Bing Za Zhi. 2022 Apr 20;30(4):367-388
pubmed: 35545562
Oncotarget. 2017 May 16;8(20):33037-33046
pubmed: 28380433
Cancer Res. 2016 Jun 1;76(11):3376-86
pubmed: 27197181
J Cosmet Dermatol. 2023 Feb;22(2):395-401
pubmed: 36065712
Onco Targets Ther. 2019 Sep 16;12:7591-7599
pubmed: 31571910
J Cancer. 2022 Jan 24;13(4):1229-1240
pubmed: 35281859
Genes (Basel). 2022 Sep 29;13(10):
pubmed: 36292645
J Cancer Res Clin Oncol. 2022 Dec;148(12):3385-3398
pubmed: 35761108
Pathol Res Pract. 2019 Jul;215(7):152444
pubmed: 31079850
BMC Cancer. 2022 Aug 29;22(1):932
pubmed: 36038839
BMC Cancer. 2021 Sep 23;21(1):1047
pubmed: 34556086
Oncotarget. 2016 Oct 4;7(40):65837-65848
pubmed: 27589564
Transl Cancer Res. 2020 Apr;9(4):2710-2720
pubmed: 35117630
Biosci Rep. 2020 Apr 30;40(4):
pubmed: 32181475
Cell Death Dis. 2022 Nov 24;13(11):994
pubmed: 36433941
Cancers (Basel). 2022 Sep 08;14(18):
pubmed: 36139536
Oncol Lett. 2021 Jan;21(1):8
pubmed: 33240414
J Obstet Gynaecol Res. 2022 Jul;48(7):1848-1858
pubmed: 35491469
Oncotarget. 2016 Mar 8;7(10):11165-93
pubmed: 26862846
Surg Oncol. 2016 Jun;25(2):74-85
pubmed: 27312032
Rheumatology (Oxford). 2018 Feb 1;57(2):388-396
pubmed: 29149307
J Am Acad Dermatol. 2002 Apr;46(4):626-36
pubmed: 11907524
J Clin Transl Hepatol. 2023 Feb 28;11(1):253-259
pubmed: 36406323
Mol Cells. 2021 Apr 30;44(4):267-278
pubmed: 33820882
Adv Exp Med Biol. 2022;1360:1-22
pubmed: 35505159
PeerJ. 2018 Aug 15;6:e5344
pubmed: 30128181
Clin Rev Allergy Immunol. 2017 Feb;52(1):20-33
pubmed: 26429706
J Cell Physiol. 2018 Sep;233(9):7424-7434
pubmed: 29663367
Biosci Biotechnol Biochem. 2020 Aug;84(8):1603-1613
pubmed: 32434425
J Immunol Res. 2022 Mar 11;2022:5164265
pubmed: 35310607
Histopathology. 2022 Oct;81(4):529-535
pubmed: 35876260
Cancer Cell Int. 2022 Oct 20;22(1):324
pubmed: 36266702